Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Synopsis - RA
3. Hands of a patient with rheumatoid arthritis
4. Rheumatoid arthritis - epidemiology
5. Symptoms and signs
6. Rheumatoid arthritis pathogenesis
7. Autoimmune pathogenesis
8. Synovial histology - T cells
9. Synovial histology - B cells
10. Aims of therapy in RA
11. Synopsis - targeting T cells
12. Targeting T-cells
13. CAMPATH-1H
14. Hypothesis
15. CAMPATH-1H therapy in man
16. CD4 reconstitution
17. Case control mortality study
18. First-dose reaction
19. CAMPATH-1H first-dose reactions
20. CAMPATH-1H summary
21. Anti-CD4 therapy for RA
22. Reasons for failure of anti-T-cell therapy in man?
23. Understanding therapeutic tolerance
24. Synopsis - targeting B cells
25. B-cells as a therapeutic target in RA
26. B-cells in synovitis
27. Steps in B-cell maturation
28. CD20
29. Rituximab
30. Rituximab in RA -phase II study design
31. Rituximab phase II: Patient demographics
32. Rituximab phase II: Baseline disease characteris.
33. Rituximab phase II: ACR responses at 24 weeks
34. Rituximab phase II: ACR responses at 48 weeks
35. Summary of adverse events from phase 2 study
36. Rituximab phase II study: Circulating B-cell counts
37. Changes in total RF (median)
38. Mean IgG (up to wk 56)
39. Mean IgM (up to week 56)
40. DANCER
41. DANCER: Study design
42. DANCER: ACR response at 48 weeks
43. DANCER - Infusion reactions
44. DANCER - Conclusions
45. Effects of Rituximab treatment
46. Synopsis - costimulation blockade
47. Co-stimulation
48. CTLA4-Ig: An immunoglobulin fusion protein
49. Phase III pivotal study (AIM)
50. AIM: Clinical characteristics
51. AIM: ACR 20 response over time
52. AIM: ACR 70 response over time
53. Mean change in radiographic scores at 1 year
54. Clinically important improvement in function
55. Abatacept - summary
56. Rituximab and Abatacept
57. Synopsis - cytokine targets
58. Anti-IL6R in RA - Phase II effects
59. Anti-IL6R in RA - Phase II effects on lipids
60. Tocilizumab inhibits joint damage progression
61. Tocilizumab study - baseline
62. Tocilizumab study - outcomes
63. Summary - Tocilizumab/MRA
64. Conclusion

Topics Covered

• Background to rheumatoid arthritis
• Rheumatoid arthritis pathogenesis
• Aims of therapy in rheumatoid arthritis
• Targeting T-cells with depleting monoclonal antibodies
• Non-depleting therapies that target T-cells
• Targeting B-cells in rheumatoid arthritis
• Co-stimulation blockade
• Targeting the interleukin-6 receptor

Links

Series:

• Monoclonal Antibodies as Therapeutic Agents

Categories:

• Clinical Practice
• Immunology

Therapeutic Areas:

• Immunology & Inflammation

Talk Citation

Isaacs, J. (2019, November 26). Monoclonal antibodies in the management of rheumatoid arthritis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/NZFU7095.
Export Citation (RIS)

Publication History

• Published on October 1, 2007
• Reviewed on November 26, 2019

Financial Disclosures

• There are no commercial/financial matters to disclose.